Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long Term, Open-label, Safety Follow Up Study Following Transplantation Of Pf-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (Rpe)) In Subjects With Acute Wet Age Related Macular Degeneration And Recent Rapid Vision Decline

Trial Profile

Long Term, Open-label, Safety Follow Up Study Following Transplantation Of Pf-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (Rpe)) In Subjects With Acute Wet Age Related Macular Degeneration And Recent Rapid Vision Decline

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2018

At a glance

  • Drugs PF 5206388 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 06 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top